Back Hepatitis C

Hepatitis C

CROI 2014: Short 6-Week Oral Treatment Works for Most Hepatitis C Patients

Interferon- and ribavirin-free treatment using sofosbuvir, ledipasvir, and a third drug for as little as 6 weeks can cure a majority of previously untreated people with genotype 1 hepatitis C, including those with traditional predictors of poor response, according to results from the SYNERGY trial presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston.

alt

CROI 2014: Faldaprevir + Interferon Cures HIV/HCV Coinfected People

The hepatitis C virus (HCV) protease inhibitor faldaprevir added to pegylated interferon and ribavirin cured nearly three-quarters of genotype 1 HIV/HCV coinfected patients in the STARTVerso4 trial, equaling response rates for people with HCV alone, according to a report this week at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) in Boston.

alt

Deaths Due to Hepatitis C Likely Undercounted

Hepatitis C is "under-documented" on death certificates of people who die with the disease, according to a report in the February 12 advance edition of Clinical Infectious Diseases. Only about 20% of people with HCV-related chronic liver disease had this listed as a cause of death, even though a majority had evidence of moderate or advanced liver fibrosis. A related study in New York City found that people with hepatitis C were at increased risk of dying, and of dying at younger ages.

alt

CROI 2014: Sofosbuvir + Ribavirin Cures 75% of Genotype 1 HIV/HCV Coinfected Patients

An interferon-free regimen of sofosbuvir plus ribavirin for 24 weeks led to sustained response in three-quarters of previously untreated genotype 1 HIV/HCV coinfected patients in the PHOTON-1 study, but a shorter 12-week regimen did not work as well for people with hepatitis C virus genotype 3, according to a report at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston.

alt

Daclatasvir + Asunaprevir Works Well for HCV 1b, but 1a Requires Interferon

An all-oral combination of Bristol-Myers Squibb's daclatasvir plus asunaprevir cured nearly 80% of patients with genotype 1b hepatitis C virus (HCV), but people with harder-to-treat HCV subtype 1a needed to add pegylated interferon and ribavirin to achieve high sustained response rates, researchers reported in the March 2014 Journal of Hepatology.

alt

CROI 2014: Hepatitis C Treatment in the Real World [VIDEO]

The opening day of the 21st Conference on Rtroviruses and Opportuistic Infections (CROI 2014) featured a press conference on advances in the treatment of hepatitis C, with a focus on how new drugs may be used in the real world, given barriers such as high cost and a shortage of experienced medical providers.

alt

Gilead 4-Drug Hepatitis C Combo Shows Modest Efficacy in Phase 2 Trial

An interferon-free regimen containing 3 direct-acting antiviral drugs plus ribavirin cured about 60% of genotype 1 hepatitis C patients treated with the highest dose for 24 weeks, according to study findings reported in the February 5 advance edition of Hepatology -- only a modest cure rate compared with some other new regimens with cure rates approaching 100%.

alt

Daclatasvir and Asunaprevir Designated as Hepatitis C "Breakthrough" Therapy

Bristol-Myers Squibb's dual regimen containing the hepatitis C virus NS5A inhibitor daclatasvir plus the HCV protease inhibitor asunaprevir has been granted "breakthrough therapy" status by the U.S. Food and Drug Administration, putting in on track for rapid approval, the company announced this week.

alt

Study Sheds Light on How Hepatitis C Virus Evades Immune System

Hepatitis C virus (HCV) appears to disable a specific variant of the IFNL3 gene, which plays a role in the immune system's response against viral infection, explaining how people with a favorable gene pattern are more likely to clear the virus naturally or with interferon-based treatment, researchers reported in the January 2014 issue of Nature Immunology.

alt